PE anti-mouse IL-33Rα (IL1RL1, ST2)

Catalog # / Size: 1326520 / 100 μg

1326515 / 25 μg

Clone: DIH9

Isotype: Rat IgG2a, κ

Immunogen: IL-33R α -hFc γ 1 fusion protein.

Reactivity: Mouse

Preparation: The antibody was purified by affinity


chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and

unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide.

Concentration: 0.2



Mouse Th2 clone D10.G4.1 was stained with anti-mouse IL-33Ra/ST2 (clone DIH9) PE (filled histogram) or rat IgG1, κ PE isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended

Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of

this reagent is ≤1.0 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each

application.

Application References:

1. Hashiguchi M, et al. 2014. Eur. J. Immunology. (FC) PubMed 2. Wiesner DL, et al. 2015. PLoS Pathog. 11:1004701. PubMed

Description:

IL-33R α , also known as ST2 or IL-1RL1, is a member of the Toll/IL-1 receptor family. It binds IL-33 and is structurally similar to IL-1R1. Two forms of the protein exist - a soluble form known as ST2 and a membrane anchored form known as ST2L. The membrane form is expressed by Th2 cells and bone marrow derived mast cells, whereas the soluble form is expressed by serum-stimulated fibroblasts.

Blocking with anti-ST2 antibodies has been shown to alleviate experimental arthritis and airway inflammation. The IL-33-ST2 axis has been reported to be important across a range of diseases including asthma, allergies, and cardiac disease.

Antigen References:

1. Yanagisawa K, et al. 1993. FEBS Lett. 318:83.

2. Schmitt E, et al. 1990. Cytokine 6:407.

3. Yanagisawa K, et al. 1992. FEBS Lett. 302:51.

4. Takagi T, et al. 1993.